Clinical Trials Browser

Phase 3 × Lymphoma, Extranodal NK-T-Cell × 90 days × Clear all

NCT05700448 2026-05-27

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Phase 3 Not yet recruiting

Lymphoma, Extranodal NK-T-Cell